

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199938093 B2
(10) Patent No. 741380

(54) Title
Platinum complex, its preparation and therapeutic application

(51)⁷ International Patent Classification(s)
C07F 015/00 A61K 031/28

(21) Application No: **199938093**

(22) Application Date: **1999.05.24**

(87) WIPO No: **WO99/61451**

(30) Priority Data

(31) Number	(32) Date	(33) Country
PV 1628-98	1998.05.27	CZ

(43) Publication Date : **1999.12.13**

(43) Publication Journal Date : **2000.02.24**

(44) Accepted Journal Date : **2001.11.29**

(71) Applicant(s)
Pliva-Lachema A.S.

(72) Inventor(s)
Frantisek Zak; Adolf Mistr; Anna Poulouva; Milan Melka; Jaroslav Turanek; Dana Zaluska



(74) Agent/Attorney
PIZZEYS, PO Box 291, WODEN ACT 2606

(56) Related Art
J.MED. CHEM. (1995), 3B(16), 3016-24
EP 503830

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07F 15/00, A61K 31/28		A1	(11) International Publication Number: WO 99/61451
			(43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/CZ99/00015		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 24 May 1999 (24.05.99)			
(30) Priority Data: PV 1628-98 27 May 1998 (27.05.98) CZ			
PLIVA-LACHEMA A.S.			
(71) Applicant (for all designated States except US): LACHEMA, A.S. [CZ/CZ]; Karásek 1, 621 33 Brno (CZ).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): ŽÁK, František [CZ/CZ]; Rerychova 4, 635 00 Brno (CZ). MISTR, Adolf [CZ/CZ]; Květnická 1614, 666 01 Tišnov (CZ). POULOVÁ, Anna [CZ/CZ]; Luční 4, 664 91 Ivančice (CZ). MĚLKA, Milan [CZ/CZ]; K sokolovně 422, 503 41 Hradec Králové (CZ). TURÁNEK, Jaroslav [CZ/CZ]; Nám. Svobody 32, 675 31 Jemnice (CZ). ZÁLUSKÁ, Dana [CZ/CZ]; Kaly 9, 594 55 Dolní Loučky (CZ).		Published With international search report.	
(74) Agent: KUBÁT, Jan; Traplová Hadr Kubát, Law and Patent Office, Přístavní 24, P.O. Box 38, 170 00 Praha 7 (CZ).			

(54) Title: PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC APPLICATION



(57) Abstract

Disclosed is a platinum complex formula (I) wherein X represents a halogen atom, B represents, independently to each other, a halogen atom, a hydroxyl group or a carboxylate group containing 1 to 6 carbon atoms, and A represents a primary tricyclic amine containing 10 to 14 carbon atoms which may be optionally substituted on the tricyclic ring by one or two alkyl group(s) each containing 1 to 4 carbon atoms, and, furthermore, an inclusion complex of the above platinum complex with beta- or gamma-cyclodextrin which may be optionally substituted by hydroxyalkyl groups containing 1 to 6 carbon atoms. There is also disclosed a process for the manufacture of the complex of formula (I) based on oxidation of a complex of divalent platinum of formula (II) with hydrogen peroxide and on optional substitution of hydroxyl groups in the obtained product with carboxylate groups by action of an acylating agent. The disclosed complexes may be used as such or as a part of pharmaceutical composition in a therapy of oncologic diseases.

M 04-05-00
-1-

150149/KB

Platinum complex, its preparation and therapeutic application**Field of the invention**

The invention relates to a new platinum complex which is useful in medicinal practice for a therapy of oncological diseases. The invention further discloses a process for the preparation of the said complex, use of the complex as a pharmaceutical and pharmaceutical compositions containing that platinum complex as the active substance.

Background of the invention

Platinum complexes effective as cytostatic agents were introduced into medicinal practice by the end of seventieths of this century. The first pharmaceutical product based on platinum complexes was cisplatin (cis-diammine-dichloroplatinum (II)). During further development of said complexes, tens of platinum complexes were synthesised and tested; among them, carboplatin became to be a substance which attained the biggest importance in oncology. Both the cited compounds, however, have to be administered only parenterally and neither of them is suitable for oral administration. The publication J.MED.CHEM(1995),38(16),3016-24 discloses hexacoordinate all-trans platinum complexes bearing halogen, hydroxyl or carboxylate groups and amine groups. . The difference between those complexes and the invention ones is in that the invention complexes have cis,trans,cis geometry. EP-A-0 503 830 refers to the platinum (IV) complexes having trans,trans,trans geometry and bearing cyclohexylamine group. The complexes cis,cis,trans are in fact prepared under specific conditions in very restricted extent, only, for example by means of an longtermed acetylation implemented under light radiation effect. Otherwise, the complexes trans,trans,trans are obtained under habitual acetylation conditions. As far as oral administration is concerned, some complexes of tetravalent platinum as disclosed in EP 328 274 and 423707 were shown as suitable. These complexes of tetravalent platinum have cis,trans,cis geometry and contain, apart from four halogen or carboxylate ligands,

AMENDED SHEET (ARTICLE 19) **LET**

M 04.05.00

two basic assymetric groups, one of them being ammin and the second being a substituted alkyl- or cycloalkylamine.

At present, platinum complexes which would express higher antitumor efficiacy in comparison with known platinum complexes are still being searched .

Now, within the present invention, certain new platinum complexes which possess higher antitumor efficiacy in comparison with platinum complexes of the prior art were found. These new complexes represent the background of the present invention .




AMENDED SHEET (ARTICLE 19) **SHEET**

11 04-05-00

Summary of the invention

According to a first aspect of the invention, there is provided a platinum complex of formula (I)




wherein

X represents a halogen atom,

B represent, independently of each other, a halogen atom, a hydroxyl group or a carboxylate group containing 1 to 6 carbon atoms, and

A represents a group $-\text{NH}_2\text{-R}$, wherein R is a tricyclic hydrocarbon moiety containing 10 to 14 carbon atoms, which may be optionally substituted on the tricyclic ring by one or two alkyl group(s) each containing 1 to 4 carbon atoms.

According to the second aspect of the invention, there is provided an inclusion complex of a platinum complex with oxidation number IV of formula I



wherein

X represents a halogen atom,

B represent, idependently to each other, a halogen atom, a hydroxyl group or a carboxylate group containing 1 to 6 carbon atoms, and

A represents a group $-\text{NH}_2\text{-R}$, wherein R is a tricyclic hydrocarbon moiety containing 10 to 14 carbon atoms, which may be substituted on the tricyclic ring by one or two alkyl group(s) each containing 1 to 4 carbon atoms,



11 04^{12a-} 05 00

with beta- or gamma-cyclodextrin which may be optionally substituted by hydroxyalkyl groups containing 1 to 6 carbon atoms.


Especially advantageous platinum complexes of the present invention are complexes of formula (I) wherein A represents an adamantylamino group and X and B have the above defined meaning, and, furthermore, their inclusion complexes with beta- or gamma cyclodextrin which may be optionally substituted as disclosed hereinabove.

Another advantageous platinum complexes of the present invention are complexes of formula (I) wherein A represents a 3,5-dimethyladamantylamino group and X and B have the above defined meaning, and, furthermore, their inclusion complexes with beta- or gamma-cyclodextrin which may be optionally substituted as disclosed hereinabove.

In another aspect of the present invention, there is provided a process for the preparation of the platinum complex of formula (I) which is characterised in that a complex of divalent platinum of formula (II)



REPLACEMENT SHEET
AMENDED SHEET (ARTICLE 19)



wherein X and A have the above defined meaning ,
 is oxidized at platinum atom by hydrogen peroxide with formation of a
 platinum(IV)dihydroxo-complex and, optionally,
 the hydroxy groups of the said complex are substituted by carboxylate groups by action
 of an acylating agent.

The invention also provides a process for the preparation of an inclusion complex
 of the platinum complex of formula (I) with beta- or gammacyclodextrin which may be
 optionally substituted by a hydroxyalkyl group containing 1 to 6 carbon atoms, said
 process being characterized in mixing a solution of the platinum complex of formula (I)
 in an organic solvent with an aqueous solution of beta- or gammacyclodextrin which is
 optionally substituted by hydroxyalkyl groups containing 1 to 6 carbon atoms, and, in
 the following step, the solvents are evaporated from the obtained solution.

Still another aspect of the invention is the platinum complex of formula (I) above
 or its inclusion complex with beta-or gammacyclodextrin for use as a pharmaceutical.

The last aspect of the invention provides a pharmaceutical composition for therapy
 of oncological diseases, characterised in that it contains, as the active substance, at least
 one platinum complex of above formula (I) or its inclusion complex with beta-or
 gamma cyclodextrin which may be optionally substituted as defined above, and at least
 one pharmaceutical excipient.

The platinum complexes of the present invention are novel chemical compounds
 as until now neither these compounds have been specifically disclosed in any document
 of the prior art nor their properties have been characterised herein nor a method of their
 production has been disclosed. The utility of these compounds as active substances in
 the therapy of oncological diseases is likewise new and inventive as it was not possible
 to deduce from the known prior art by an obvious way that the presence of primary



11 04.05.00

tricyclic amine ligand in tetravalent platinum complexes would lead to a basic increase of antitumor activity of the new compounds of the present invention.

Main advantages of the platinum complexes of the present invention in comparison with the so far known platinum complexes and namely in comparison with platinum complexes disclosed in the patents EP 328274 and EP 423707 are based not only on their higher efficiency at oral administration and low toxicity but namely on broader spectrum of their antitumor activity.

In further part, the invention will be described in more detail by the means of examples of concrete arrangement. It must be understood that these examples are for illustrative purposes and that they by no means limit the scope of the invention which is rather defined by the patent claims.

Detailed description of the invention

Example 1

Synthesis of af-bis (acetato)-b-(1-adamantylamine)-c-ammin-de-dichloroplatinum (IV) complex (hereinafter will be called as „LA-12“) [(OC-6-43)-bis(acetato)(1-adamantanamine)amminedichloroplatinum(IV)]

Stir 6.25 g (13.3 mmol) of b-(1-adamantylamine)-c-ammin-de-dichloro-af-dihydroxoplatinum(IV) complex [(OC-6-43)-(1-adamantanamine)amminedichlorodihydroxoplatinum(IV)] at room temperature with an excess of acetic anhydride (50.2 ml, 532 mmol). During the time, a solid continuously precipitates from the original solution. After termination of the precipitation, filter the solid and wash it with a small amount of acetic anhydride and ether. After drying in a vacuum dryer, 4.28 g (58.2%) of the title product is obtained.

The identity of the obtained product was confirmed by ¹H and ¹³C nuclear magnetic resonance spectrum and by infrared spectrum and its purity was determined by high performance liquid chromatography.

Elemental analysis of the product for C₁₄H₂₆Cl₂N₂O₄Pt:

SUBSTITUTE SHEET
AMENDED SHEET (ARTICLE 19)



11.04.05.00

	C(%)	H(%)	N(%)	Cl(%)
found	30.24	4.75	4.99	12.81
calculated	30.44	4.74	5.07	12.84

Example 2

Synthesis of af-bis(acetato)-b-(1-amino-3,5-dimethyladamantane)-c-ammin-de-dichloroplatinum (IV) complex (hereinafter will be called as „LA-15“) [(OC-6-43)-bis(acetato)(1-amino-3,5-dimethyladamantane)amminedichloroplatinum(IV)]

Stir 0.96 g (1.93 mmol) of b-(1-amino-3,5-dimethyladamantane)-c-ammin-de-dichloro-af-dihydroxoplatinum(IV) complex [(OC-6-43)-(1-amino-3,5-dimethyladamantan)amminedichlorodihydroxoplatinum(IV)] at room temperature with an excess of acetic anhydride (8 ml, 84.7 mmol). After dissolution, add 10 ml of ether to the reaction mixture. Continue in stirring until the formation of a precipitate terminates. Filter the precipitated solid ,wash with ether and dry in a vacuum dryer. The yield is 0.72 g (64.3%) of the title product.

The identity of the obtained product was confirmed by ¹H and ¹³C nuclear magnetic resonance spectrum and by infrared spectrum and its purity was determined by high performance liquid chromatography.

Elemental analysis of the product for C₁₆H₃₀Cl₂N₂O₄Pt:

	C(%)	H(%)	N(%)	Cl(%)
found	32.88	5.21	4.75	12.31
calculated	33.11	5.21	4.83	12.22

Example 2a

Synthesis of b-(1-adamantylamine)-c-ammin-de-dichloro-af-dihydroxoplatinum(IV) complex (hereinafter will be called as LA-11)

Suspend 8.01 g (18.44 mol) of cis-(1-adamantylamine)-ammin-dichloroplatinum (II) complex in 120 ml of water at room temperature. Add a stoichiometric excess (20 ml) of 30% (w/w) aqueous solution of hydrogen peroxide to the suspension , heat the reaction mixture at 80°C for one hour and then cool to the room temperature. Separate the solid by filtration, wash with water and dry partially. Extract and wash the product



AMENDED SHEET (ARTICLE 19) **HEET**

M 04-05-00

with dimethylformamide in total amount of 150 ml. Remove the rests of dimethylformamide by washing with ether. After drying in vacuum dryer, the yield is 6.45 g, i.e. 74.6% of theory (related to the starting platinum (II) complex).

Identity of the product was confirmed by infrared spectral analysis and the purity was determined by high performance liquid chromatography.

Elemental analysis of the obtained product (for $C_{10}H_{22}Cl_2N_2O_2Pt$):

	C(%)	H(%)	N(%)	Cl(%)
found	25.75	4.76	5.94	15.10
calculated	25.65	4.74	5.98	15.14

Example 3

Synthesis of inclusion complex of the compound LA-12 with hydroxypropyl-beta-cyclodextrin (hereinafter will be called as „inclusion drug form of LA-12“)

Dissolve the compound LA-12 in acetone to obtain the final concentration of 20g/l. Add hydroxypropyl-beta-cyclodextrin (164g/l) to the obtained solution. Add slowly a buffered aqueous phase of 100mM Hepes of pH 7.3 under stirring at room temperature to that mixture until final volume ratio of acetone and aqueous phase is 1:10. The undissolved cyclodextrin dissolves rapidly even after first additions of the aqueous phase (up to 10% of the total volume of the aqueous phase). Finally, remove acetone and water from the solution of the inclusion complex by lyophilisation.

Screening of antineoplastic activity of the compounds of the present invention has been performed by testing these compounds at experiments in vivo, on animals with experimental tumors such as mice leucaemia L1210 in ascitic form (IP-L1210) or in solid form (SC-L1210) grown on DBA2 mice, Gardner lymphosarcoma in solid and ascitic form (LsG) grown on C3H mice, Ehrlich tumor in solid (STE) and ascitic form (ATE) grown on NMRI mice, tumor MC2111 (transplantable mammal adenocarcinoma) grown on DBA1 mice, metastasing melanocarcinoma B16 in solid and ascitic form (SC-B16, IP-B16) grown on C57B16 mice and Lewis metastasing



AMENDED SHEET (ARTICLE 19) I E E T

M 04⁷⁻ 05 00

lung carcinoma (LL) grown on C57B16 mice, namely by a method of V.Jelinek (Neoplasma 12,469(1965), ibid. 7,146(1960)).

The survival time was evaluated and the optimum dosage was calculated, apart from point estimations evaluated by Student's t-test, by proportional risk model of Cox and by the procedure of Carter (Carter W.H. et al.: Cancer Res. 42,2963 (1982)). Curves of activity drawn according to this calculation procedure allow to calculate the optimum dosage and to estimate toxic dosages. This procedure allows to evaluate not only the effect at a monotherapy but also the overall toxicity and influences of components of a combined therapy. Therefore, dependences between dose and activity were modelled and evaluated in some examples also by this method.

For purposes of this invention, the term „therapy“ means an inhibition of characteristics signs and symptoms of a disease on biological objects carrying a tumor, namely an inhibition of a tumor growth and inhibition of survival time decrease of a biological object. The growth of a tumor may be observed both clinically and at experiments in vivo, i.e. on experimental animals. The evaluation of the growth of a tumor may be performed by weighing of the tumor tissue or measuring of the tumor size.

Such favourable therapeutical effect of compounds of the present invention at mice females of C3H strain was proven by decrease of the tumor weight at animals with solid form of Gardner lymphosarcoma (SC-LsG), with STE, SC-B16, SC-LL and MC-2111, namely at oral administration of compounds of this group of chemicals. Statistically significant ($p \leq 0.05$) or even highly significant ($p \leq 0.01$) decrease of average mass of tumors was demonstrated in comparison with the control, i.e. untreated group.

Likewise, the compounds of the present invention prolong the survival time of suitable biological objects, e.g. of mice with IP-L1210, MC211, SC-L1210, IP-LsG and ATE tumors, marginally also of those with IP-B16 and IP-LsG, namely at oral administration. As the nature of the above used test systems is lethal, the antitumor effect of the compounds of the invention may be documented by comparison of survival time of treated animals (which survive longer) with untreated control animals. In typical



AMENDED SHEET (ARTICLE 19) **IEET**

NO. 05.00

experiments (see Examples), one experimental group usually consisted from ten animals and the treated groups have survived statistically significantly longer than the control, i.e. untreated groups.

For to use their antitumor effects, the disclosed compounds may be administered to suitable biological objects, namely mammals, in suitable application form and by conventional ways of administration. They may be administered alone or, advantageously, as the active substances together with whatever suitable and nontoxic pharmaceutical carrier, dissolved or suspended, e.g. in water, a buffer, a physiological saline, in a solution of methylcellulose, polyethyleneglycol, polypropyleneglycol etc. Oral administration is the most advantageous one. The optimum dose is dependent on the type of the tumor which should be treated, on the type of the biological object to be treated, on its weight and/or body surface, on the localisation of the tumor, on its morphological type, on the dosage regimen etc. It is apparent from the performed biological tests that, e.g., the effective single dose of orally administered LA-12 is only 10 mg/kg (30 mg/m^2) for IP-L1210, whereby LA-2 (see below) exhibits no effect at this dose. At intermittent administration (1st, 4th and 9th day) of a typical dose of LA-12, the optimum dose for DBA2 mice with leukaemia L1210 is 22.9mg/kg p.o. x 3 ($68.7 \text{ mg/m}^2 \times 3$) and at continual administration (1st-9th day) the optimum dose for the same mice is 9.6 mg/kg p.o. x 9 ($28.8 \text{ mg/m}^2 \times 9$).

The toxicity of compounds of the invention is low; the LD50 value at NMRI mice can be found above 600 mg/kg p.o.

It is apparent that useful therapeutic effects can be expected at dosages which are absolutely nontoxic for organisms of mammals. According to the biological tests performed, the tolerable and effective single oral dose for a human can be expected on a level of 30 mg/m^2 .

In the following tests which will demonstrate the antitumor effect of compounds of the present invention the following prior art compounds were used for reference: af-bis(acetato)-b-ammin-cd-dichloro-e-(cyclohexylamine)platinum (IV) complex [(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV)] (JM216, Johnson Matthey Technology Centre, Reafing, Berkshire, Great Britain, Kelland et al., 1993)



M 04-05-00

which is hereinbelow called as compound LA-2, and cis-diammin-dichloroplatinum(II) complex which is the active substance of a medicinal preparation Platidiam 10 .

Example 4

Illustration of antitumor activity of af-bis(acetato)-b-(1-adamantylamine)-c-ammin-de-dichloroplatinum(IV)complex (compound (I), A=1-adamantylamine, „LA-12“) in mice after single oral administration and comparison with af-bis(acetato)-b-ammin-cd-dichloro-e-(cyclohexylamine)platinum (IV) complex (compound (I), A=



AMENDED SHEET (ARTICLE 19) **EET**

cyclohexylamine, code JM216 - Johnson Matthey Technology Centre, „LA-2“) and with cis-diammin-dichloroplatinum(II) complex (NSC 119875, active substance of the preparation PLATIDIAM 10 inj.sicc.)

One hundred and fifty mouse females of DBA2 strain of approximate weight of 18 g were sorted into fourteen groups: one reference group (21 animals) and thirteen experimental groups (9-10 animals). All animals were inoculated intraperitoneally with a lethal dose of ascitic liquid from L1210 leukaemia. Ten of the experimental groups were treated with compounds LA-12 and LA-2 in water suspensions prepared ad hoc immediately before the application. The suspensions contained such amounts of the respective compound so that the experimental animals obtained one day after the inoculation of the tumor the dosages of 160,80,40,20 and 10 mg/kg resp., in volumes of 0.2-0.4 ml. PLATIDIAM was applied to three groups subcutaneously, in a form of an isotonic aqueous solution prepared by dissolution of the lyophilised powder in water for injections immediately before the application. The animals were monitored to determine their survival time. The dependence of the survival time value on the applied dose was evaluated in comparison with the reference group. The single estimated time points as biological responses were evaluated by a test of equivalence of two mean values (Student's t-test) under presumption of logarithmic/normal character of distribution of temporal values and under presumption of possible unknown disseminations (Roth et al., 1962). Geometric mean value was calculated from single values of the survival time. Those mean values of the test criterion the difference of which exceeded the critical value at significance level of 5% were evaluated as statistically significant.

It has been observed that animals treated with LA-12 had statistically significant (t-test, $p \leq 0.05$) higher mean value of survival time in the dosage group of 10mg/kg p.o., namely by 55% in comparison with the untreated control group. Platidium, at a dose of 5mg/kg s.c., increased the mean value of survival time by 32% against the control, this difference in values however has not been statistically significant in comparison with the control group. No effect has been proven at LA-2.

The results are summarized in the following table :

Tab 1.

Antitumor effect of compounds LA-2 and LA-12 in comparison with PLATIDIAM inj. at animals with leucaemia L1210

Mice DBA2, females, 16.6-19.1 g. Transplantation of the tumor by i.p., inoculum of 10^6 tumor cells. Beginning with the therapy 1st day after transplantation (1 x p.o., Platidiam 1x s.c. 1st day).

The table lists, with respect to the respective dosages, the mean values of survival time, confidentiality intervals of the geometric mean for $P = 1 - \alpha = 0.95$ and relative values of mean survival time as a percentage of that of the control group.

Compound	Dosage (mg/kg)	n (j)	Geom. mean (days)	Confident. interval (days)	Survival (in % of control)	Note
control	0	21	12.7	(10.0 ; 16.1)	100	
Platidiam	10	10	6.1	(5.5 ; 6.8)	48	
	5	10	16.7	(9.4 ; 29.6)	>132	2)
	2.5	10	14.2	(8.6 ; 23.3)	112	
LA-2	160	10	8.0	(5.2 ; 12.2)	63	
	80	10	10.7	(6.6 ; 17.4)	85	
	40	10	10.3	(6.3 ; 16.7)	81	
	20	10	11.9	(6.9 ; 20.4)	94	
	10	10	12.5	(7.2 ; 21.7)	99	
LA-12	160	10	9.3	(5.8 ; 14.9)	73	
	80	10	9.5	(5.8 ; 15.6)	75	
	40	10	12.3	(7.8 ; 19.4)		97
	20	10	13.3	(8.2 ; 21.6)		105
	10	10	19.6	(14.6 ; 26.3)		155 1)

n = amount of animals in a group

1) Statistically significant difference of the mean value against the control at significance level $\alpha = 0.05$

2) One animal surviving 94th day destroyed without tumor

Example 5

Illustration of antitumor activity of af-bis(acetato)-b-(1-adamantylamine)-c-ammin-dichloroplatinum(IV)complex (compound (I), A=1-adamantylamine, „LA-12“) in mice after intermitent oral administration and comparison with af-bis(acetato)-b-ammin-cd-dichloro-e-(cyclohexylamine)platinum (IV)complex (compound (I), A= cyclohexylamine, code JM216 „LA-2“ - Kelland et al., 1993) and with cis-diammin-dichloroplatinum(II) complex (NSC 119875, active substance of the preparation PLATIDIAM 10 inj.sicc.)

In a similar experiment on animals with leucaemia L1210, the compound (I) (A = adamantylamine, LA-12) was administered repeatedly in three daily doses, namely at 1st, 4th and 9th day after inoculation together with LA-2 p.o. and Platidium s.c. in the same regimen.

It has been observed that animals treated with LA-12 had statistically significant (t-test, $p \leq 0.05$) higher average value of survival time in the dosage group of 4mg/kg/day p.o. x 3 (148%) in comparison with the untreated control group. The compound LA-2 exhibited the same effect (148%) only at twofold dose, i.e. in a dose of 8 mg/kg/day p.o. x 3. Optimum dose of LA-12 as calculated according to Carter was only 4.55 mg/kg/day p.o. x 3, while that of LA-2 was 10.96 mg/kg/day p.o. x 3, i.e. more than twofold. A characteristic compound of the present invention is thus more than twice as effective as a typical compound of the above cited patents in its optimum therapeutical regimen.

The results are summarized in the following table :

Tab 2.

Antitumor effect of compounds LA-2 and LA-12 in comparison with PLATIDIAM inj. at animals with leucaemia L1210

Mice DBA2, females, 19.8-21.2 g. Transplantation of the tumor by i.p., inoculum of 10^6 tumor cells. Beginning with the therapy 1st day after transplantation (3 x p.o., Platidium 3x s.c. 1st, 5th and 9th day).

- 12 -

The table lists, with respect to the respective dosages, the mean values of survival time, confidentiality intervals of the geometric mean for $P = 1 - \alpha = 0.95$ and relative values of mean survival time as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Geom. mean (days)	Confident. interval (days)	Survival (in % of control)	Note
control	0	10	15.7	(11.6 ;21.1)	100	
Platidium	4	10	16,6	(14.8 ;18.6)		106
	2	10	26.3	(24.5 ;28.2)		168 2)
	1	10	28.0	(22.0 ;35.6)		178 2)
LA-2	8	10	23.2	(16.8 ;32.0)		>148
1),4)						
	4	10	18.5	(14.7 ;23.2)		118
	2	10	20.2	(12.4 ;32.8)		>129 4)
LA-12	8	10	18.5	(13.5 ;25.3)		118
	4	10	23.0	(19.8 ;26.5)		147 1)
	2	10	19.0	(12.7 ;28.4)		>121 4)

n = amount of animals in a group

Statistically significant difference of the mean value against the control at significance level $\alpha =$ 1) 0.05, 2) 0.01, 3) 0.001

4) One animal surviving 50th day

Example 6

Illustration of antitumor activity of af-bis(acetato)-b-(1-adamantylamine)-c-ammin-de-dichloroplatinum(IV)complex (compound (I), A=1-adamantylamine, „LA-12“) in mice with leucaemia L1210 after continual and intermitent oral administration and comparison with af-bis(acetato)-b-ammin-cd-dichloro-e-(cyclohexylamine)platinum (IV)complex (compound (I), A= cyclohexylamine, code JM216, „LA-2“ - Kelland et al., 1993) and with cis-diammin-dichloroplatinum(II) complex (NSC 119875, active substance of the preparation PLATIDIAM 10 inj.sicc.)

- 13 -

In an experiment on animals with leucaemia L1210 which was arranged analogically as in Examples 4 and 5, the compound (I) (A = adamantylamine, LA-12) was administered repeatedly both in nine daily doses, namely at 1st- 9th day after inoculation, and also intermitently at 1st, 4th and 9th day together with LA-2 p.o. in such a way that cumulative doses were identical in both regimens. Platidiam was administered subcutaneously .

The compound LA-12 increased statistically significantly the survival time value in comparison with the control group in the dosage of 6mg/kg/ p.o.x 9, namely by 130% and it has been evaluated as antitumor effective similarly as Platidiam in dosages 8 and 4 mg/kg s.c. x 1. The compound LA-2 didnot increase statistically significantly the survival time in comparison with the control group in any of the dosage groups and is thus evaluated as antitumor uneffective.

In the intermitent regimen (1st, 5th and 9th day after inoculation) no effect was proven by means of point estimations.

The evaluation of the dose/effect dependence of LA-12 shows that continual therapeutical regimen is more advantageous at the same cummulative dose.

The results are summarized in the following table :

Tab 3.

Antitumor effect of compounds LA-2 and LA-12 in comparison with PLATIDIAM inj. at animals with leucaemia L1210; comparison of continual therapeutic regimen with intermitent regimen.

Mice DBA2, females, 19.3-21.4 g. Inoculation of the tumor by i.p., inoculum of 10^6 tumor cells. Beginning with the therapy 1st day after inoculation (9 x p.o. 1th-9th and 3x 1th, 5th and 9th day resp., Platidiam 1x s.c. 1st day).

The table lists, with respect to the respective dosages, the mean values of survival time, confidentiality intervals of the geometric mean for $P = 1 - \alpha = 0.95$ and relative values of mean survival time as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Geom. mean (days)	Confident. interval (days)	Survival (in % of control)	Note
control	0	12	11.6	(7.7 ;17.4)	100	
Platidiam	8	10	23.7	(20.1 ;27.9)	204	2)
	4	10	20.2	(15.0 ;27.2)	174	1)
	2	10	17.9	(12.1 ;26.5)	155	
LA-2	12	10	11.5	(7.7 ;17.1)	99	1-9th day
	6	10	20.0	(11.2 ;35.9)	173	
	3	10	18.7	(10.1 ;34.7)	162	
LA-12	12	10	13.6	(9.0 ;20.8)	118	1-9th day
	6	10	16.6	(12.7 ;55.8)	230	1)
	3	10	11.1	(6.5 ;19.0)	96	
LA-2	36	10	15.1	(7.5 ;30.1)	130	1,5,9th day
	18	10	18.6	(10.8 ;32.0)	160	
	9	10	11.4	(6.7 ;19.5)	99	
LA-12	36	10	15.9	(7.6 ;32.9)	137	1,5,9th day
	18	10	18.3	(9.5 ;35.4)	158	
	9	10	13.3	(8.1 ;21.7)	115	

n = amount of animals in a group

Statistically significant difference of the mean value against the control at significance level $\alpha = 1) 0.05, 2) 0.01, 3) 0.001$

Example 7

Illustration of antitumor activity of af-bis(acetato)-b-(1-adamantylamine)-c-ammin-de-dichloroplatinum(IV) complex (compound (I), A=1-adamantylamine, „LA-12“), inclusion drug form of LA-12 and af-bis(acetato)b-(1-amino-3,5-dimethyladamantan)-c-ammin-de-dichloroplatinum (IV) complex (compound (I), A= 1-amino-3,5-dimethyladamantane, „LA-15“) in mice with leucaemia L1210 after continual oral administration and comparison with af-bis(acetato)-b-ammin-cd-dichloro-e-

(cyclohexylamine)platinum (IV)complex (compound (I), A= cyclohexylamine, code JM216, „LA-2“ - Kelland et al., 1993) and with cis-diammin-dichloroplatinum(II) complex (NSC 119875, active substance of the preparation PLATIDIAM 10 inj.sicc.)

In an experiment with animals with leucaemia L1210 which was arranged analogically as in Examples 4 ,5 and 6, the compound LA-12, its new drug form and compound LA-15 were administered repeatedly in nine daily doses, namely at 1st- 9th day after inoculation, together with LA-2 p.o. in the same regimen. Platidiam was administered subcutaneously .

The compound LA-12, its inclusion drug form and LA-15 increased the survival time value statistically highly significant in comparison with the control group in the dosages used, namely by 130% and they have been evaluated as antitumor effective similarly as Platidiam in dosages 4 mg/kg s.c. x 1 (123%) and LA-2 in the dosage 3mg/kg/day p.o. x 9 (114%) .

The results are summarized in the following table :

Tab 4.

Antitumor effect of compounds LA-2 , LA-12, new drug form of LA-12 and LA-15 in comparison with PLATIDIAM inj. at animals with leucaemia L1210 ; continual therapeutic regimen.

Mice DBA2, females, 18.0-19.7 g. Inoculation of the tumor by i.p., inoculum of $1.2 \cdot 10^6$ tumor cells. Beginning with the therapy 1st day after inoculation (9 x p.o. 1th-9th day , Platidiam 1x s.c. 1st day).

The table lists, with respect to the respective dosages, the mean values of survival time, confidentiality intervals of the geometric mean for $P = 1 - \alpha = 0.95$ and relative values of mean survival time as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Geom. mean (days)	Confident. interval (days)	Survival (in % of control)	Note
control	0	10	22.5	(19.6 ;25.9)	100	

- 16 -

Platidium	4	10	50.2	(27.9 ;90.2)	>223 ¹⁾	5/10
4)						
LA-2	12	10	24.4	(16.8 ;35.3)	108	
	6	10	30.8	(18.9 ;50.1)	137	1)
	3	10	48.1	(41.4 ;56.0)	214	3)
LA-12	12	10	47.2	(43.6 ;51.2)	210	3)
	6	10	38.8	(29.7 ;50.8)	172	2)
	3	10	44.6	(37.3 ;53.3)	198	3)
LA-12,drug form	12	10	51.1	(48.4 ;53.9)	227	3)
	6	10	46.4	(39.1 ;55.1)	206	3)
	3	10	40.0	(31.7 ;50.4)	177	3)
LA-15	12	10	29.3	(18.1 ;47.6)	130	
	6	10	48.8	(41.9 ;56.9)	217	3)
	3	10	40.5	(30.0 ;54.8)	180	2)

n = amount of animals in a group

Statistically significant difference of the mean value against the control at significance level $\alpha =$ 1) 0.05, 2) 0.01, 3) 0.001

4) LTS - Long Term Survivors (amount of surviving animals in a group)

Example 8

Illustration of antitumor activity of af-bis(acetato)-b-(1-adamantylamine)-c-ammin-de-dichloroplatinum(IV)complex (compound (I), A=1-adamantylamine, „LA-12“), in mice with Gardner lymphosarcoma after single oral administration and comparison with af-bis(acetato)-b-ammin-cd-dichloro-e-(cyclohexylamine)platinum (IV)complex (compound (I), A= cyclohexylamine, code JM216, „LA-2“ - Kelland et al., 1993) and with cis-diammin-dichloroplatinum(II) complex (NSC 119875, active substance of the preparation PLATIDIAM 10 inj.sicc.)

Two hundred mice females of C3H strain weighing of about 25 g were sorted into ten groups, namely one control and nine experimental ones, each containing 20 animals.

Lethal dose of a tumor homogenate from Gardner lymphosarcoma was transplanted subcutaneously to all animals. Experimental groups were treated with compounds LA-12 and LA-2 in water suspension prepared ad hoc immediately before the application. The suspensions contained such amounts of the respective compound so that the experimental animals obtained the fifth day after the inoculation of the tumor the dosages of 32, 8 and 2 mg/kg resp., in volumes of 0.2-0.4 ml; PLATIDIAM was applied once in a dose of 8, 4 and 2 mg/kg s.c. Half of the animals in each dosage group was destroyed the 14th day after inoculation in ether narcosis and tumors were surgically isolated from bodies. The mass of a tumor at each of the animals was determined by weighing. The second halves of animals were left for monitoring the survival time.

It has been observed that animals treated with LA-12 had statistically significant (t-test, $p \leq 0.05$) lower average mass of a tumor (77%) at a dose of 32 mg/kg p.o. in comparison with the control group (100%). No effect has been observed at LA-2 of the prior art.

The results are summarized in the following table :

Tab 5.

Antitumor effect of compounds LA-2 and LA-12 in comparison with PLATIDIAM inj. at animals with solid form of Gardner lymphosarcoma.

Mice C3H, females, 20.7 - 28.3 g. Transplantation of the tumor by s.c., 0.2 ml of tumor homogenate. Beginning with the therapy 5th day after transplantation (1 x p.o., Platidiam 1x s.c. 5th day).

The table lists, with respect to the respective dosages, average values of tumor mass, confidentiality intervals of the arithmetic mean for $P = 1 - \alpha = 0.95$ and relative values of mean tumor mass as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Arithm. mean (g)	Confident. interval (g)	Tumor mass (%)	Note
----------	-----------------------	----------	------------------------	-------------------------------	----------------------	------

control	0	10	6.24	(5.13 ;7.35)	100	
Platidium	8	10	1.64	(0.92 ;2.36)		26 3)
	4	10	3.68	(3.06 ;4.30)	59	3)
	2	10	5.19	(4.31 ;6.06)	83	
LA-2	32	10	6.44	(5.61 ;7.28)	103	
	8	10	6.19	(5.52 ;6.87)		99
	2	10	5.61	(4.67 ;6.55)		90
LA-12	32	10	4.80	(4.26 ;5.34)		77 1)
	8	10	5.46	(4.43 ;6.49)		88
	2	10	5.02	(4.28 ;5.75)	80	

n = amount of animals in a group

Statistically significant difference of the mean value against the control at significance level $\alpha = 1) 0.05, 2) 0.01, 3) 0.001$

Example 9

Illustration of antitumor activity of af-bis(acetato)-b-(1-adamantylamine)-c-ammin-de-dichloroplatinum(IV)complex (compound (I), A=1-adamantylamine, „LA-12“), in mice with mammal adenocarcinoma MC2111 after repeated continual oral administration and comparison with af-bis(acetato)-b-ammin-cd-dichloro-e-(cyclohexylamine)platinum(IV)complex (compound (I), A= cyclohexylamine, code JM216, „LA-2“ - Kelland et al., 1993) and with cis-diammin-dichloroplatinum(II) complex (NSC 119875, active substance of the preparation PLATIDIAM 10 inj.sicc.)

One hundred and thirty mice females of DBA1 strain weighing of about 20 g were sorted into twelve groups, namely one control and eleven experimental ones, each containing 10 animals. Lethal dose of tumor homogenate was inoculated subcutaneously to all animals. Experimental groups were treated with compounds LA-2, LA-12 and LA-15 in water suspension prepared ad hoc immediately before the application. The suspensions contained such amounts of the respective compounds so that the experimental animals obtained the dosages of 12, 6 and 3 mg/kg/day p.o x 9

resp., in volumes of 0.2-0.4 ml; PLATIDIAM was applied once in a dose of 8 and 4 mg/kg s.c. in volume of 0.2 and 0.4 ml, the fifth day after inoculation.

The animals from the control group and from each dosage group were weighed and sizes of tumors were measured at 14th day after inoculation. One half of animals from the control group was destroyed in ether narcosis and tumors were surgically isolated from bodies. A dependence of a mass of a tumor on its size was evaluated by regression analysis. The mass of a tumor at each of the animals was determined from this regression function. The tumor masses were evaluated in case of point estimations by a test of equivalence of two mean values (Student's t-test) under presumption of normal character of distribution of mass values and under presumption of possible unknown disseminations. Arithmetic mean value was calculated from the single values of the tumor mass. Those differences in mean values at which the value of test criterium exceeded the critical value at 5% significance level were evaluated as statistically significant.

The dependence of survival time on the applied dose has been evaluated in comparison with the untreated control. The time has been evaluated analogically as at leucaemias and ascitic tumors, namely in case of estimated time points by a test of equivalence of two mean values (Student's t-test) under presumption of logarithmic/normal character of distribution of temporal values and under presumption of possible unknown disseminations (Roth Z., Josifko M., Maly V., Trcka V.: Statistické metody v experimentální medicíně, SZN Prague 1962, p. 278). Geometric mean value was calculated from single values of the survival time. Those mean values of the test criterium the difference of which exceeded the critical value at the 5% significance level were evaluated as statistically significant.

It has been observed that animals treated with LA-12 had statistically significant (t-test, $p \leq 0.05$) lower average mass of a tumor (86 %) at a dose of 3mg/kg/day p.o. x 9. Furthermore, they had statistically significant (t-test, $p \leq 0.05$) higher mean value of survival time (128%) in comparison with the untreated control group (100%). Other tested substances (except of Platidiam) had no statistically significant difference in point estimations of survival time in comparison with the control group.

The compound LA-12, as well as Platidium, was evaluated as antitumor effective. No effect was observed at LA-2 of the prior art.

The results are summarized in the following table :

Tab 6-1.

Antitumor effect of compounds LA-2, LA-12 and LA-15 in comparison with PLATIDIAM inj. at animals with solid form of mammal adenocarcinoma MC2111: continual therapeutical regimen .

Mice DBA1, females, 20.4 - 21.8 g. Inoculation of the tumor by s.c., 0.2 ml of tumor homogenate, dilution 1:1. Beginning with the therapy 5th day after inoculation (9 x p.o., 5th-13th day, Platidium 1x s.c. 5th day).

The table lists, with respect to the respective dosages, mean values of survival time, confidentiality intervals of the geometric mean for $P = 1 - \alpha = 0.95$ and relative values of mean survival times as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Geom. mean (days)	Confident. interval (days)	Survival (in % of control)	Note LTS
control	0	10	21.6	(19.4 ;24.2)	100	
Platidium	8	10	35.1	(25.3 ;48.7)		>162 ²⁾ 1/10
	4	10	34.3	(23.0 ;51.3)		>158 ¹⁾ 1/10
LA-2	12	10	21.7	(17.9 ;26.3)	100	
	6	10	24.9	(19.8 ;32.9)		115
	3	10	24.5	(21.0 ;28.5)		113
LA-12	12	10	25.1	(21.9 ;28.8)		116
	6	10	25.3	(20.0 ;32.0)		117
	3	10	27.7	(24.8 ;30.9)	128	2)
LA-15	12	9	25.5	(20.7 ;31.4)		118
	6	10	27.6	(21.8 ;35.0)		127
	3	10	25.4	(21.7 ;29.7)	117	

n = amount of animals in a group

Statistically significant difference of the mean value against the control at significance level $\alpha = 1) 0.05, 2) 0.01$

LTS - Long Term Survivors ; the amount of animals destroyed at 120th day

Tab 6-2.

Antitumor effect of compounds LA-2, LA-12 and LA-15 in comparison with PLATIDIAM inj. at animals with solid form of mammal adenocarcinoma MC2111: continual therapeutical regimen .

Mice DBA1, females, 20.4 - 21.8 g. Inoculation of the tumor by s.c., 0.2 ml of tumor homogenate, dilution 1:1 . Beginning with the therapy 5th day after inoculation (9 x p.o., 5th-13 day, Platidium 1x s.c. 5th day).

The table lists, with respect to the respective dosages, mean values of tumor mass, confidentiality intervals of the arithmetic mean for $P = 1 - \alpha = 0.95$ and relative values of mean tumor masses as a percentage of that of the control group.

--						
Compound	Dosage	n	Arithm. mean	Confident. interval	Tumor mass	Note
	(mg/kg/day)	(j)	(g)	(g)	(%)	

--						
control	0	10	4.65	(4.34 ;4.96)	100	
Platidium	8	9	3.20	(2.90 ;3.49)		69 3)
	4	9	3.53	(3.01 ;4.05)	76	2)
LA-2	12	8	3.59	(2.94 ;4.24)	77	2)
	6	10	3.86	(3.11 ;4.61)		83
	3	10	4.00	(3.68 ;4.32)		86 2)
LA-12	12	10	4.05	(3.82 ;4.28)		87 2)
	6	10	3.73	(3.25 ;4.21)		80 2)
	3	10	4.02	(3.63 ;4.41)		86 1)
LA-15	12	9	3.74	(3.28 ;4.21)		80 2)

- 22 -

6	10	3.95	(3.50 ;4.40)	85	1)
3	10	4.19	(3.91 ;4.47)	90	1)

n = amount of animals in a group

Statistically significant difference of the mean value against the control at significance level $\alpha = 1) 0.05, 2) 0.01$

LTS - Long Term Survivors ; the amount of animals destroyed at 120th day

Example 10

Illustration of antitumor activity of af-bis(acetato)-b-(1-adamantylamine)-c-ammin-de-dichloroplatinum(IV)complex (compound (I), A=1-adamantylamine, „LA-12“), in mice with ascitic Ehrlich tumor after repeated oral administration and comparison with af-bis(acetato)-b-ammin-cd-dichloro-e-(cyclohexylamine)platinum (IV)complex (compound (I), A= cyclohexylamine, code JM216, „LA-2“ - Kelland et al., 1993) and with cis-diammin-dichloroplatinum(II) complex (NSC 119875, active substance of the preparation PLATIDIAM 10 inj.sicc.)

Two hundred mice females of ICR strain weighing of about 24 g were sorted into ten groups, namely one control and nine experimental ones, each containing 20 animals. Lethal dose of ascitic liquor from ATE was inoculated intraperitoneally to all animals. Experimental groups were treated with compounds LA-12 and LA-2 in water suspension prepared ad hoc immediately before the application. The suspensions contained such amounts of the respective compounds so that the experimental animals obtained the dosages of 12, 6 and 3 mg/kg/day p.o x 9 resp., in volumes of 0.2-0.4 ml; PLATIDIAM was applied once in a dose of 8, 4 and 2 mg/kg s.c. in volume of 0.2 and 0.4 ml, the first day after inoculation. Half of the animals in each dosage group was destroyed the 10th day after inoculation in ether narcosis, the ascits were sucked out after laparotomy and the mass of a tumor at each of the animals was determined from the difference of mass before and after sucking out the ascit. Remaining animals were left for monitoring the survival time.

It has been observed that animals treated had lower average mass of a tumor in comparison with the untreated control (Tab. 7 -1). However, the mean survival time

increase was statistically highly significant ($p \leq 0.01$) in comparison with untreated control only at LA-12 and at Platidiam, but not at LA-2 (Tab. 7-2).

Tab 7-1.

Antitumor effect of compounds LA-2 and LA-12 in comparison with PLATIDIAM inj. at animals with ascitic form of Ehrlich tumor (ATE); continual therapeutical regimen.

Mice ICR, females, 23.7 - 25.4 g. Inoculation of the tumor by i.p., inoculum of 0.2 ml of ascite. Beginning with the therapy 1st day after inoculation (9 x p.o., 1st-9th day, Platidiam 1x s.c. 1st day).

The table lists, with respect to the respective dosages, mean values of tumor mass, confidentiality intervals of the arithmetic mean for $P = 1 - \alpha = 0.95$ and relative values of mean tumor masses as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Arithm. mean (g)	Confident. interval (g)	Tumor mass (%)	Note
control	0	8	2.65	(1.74 ;3.56)	100	
Platidiam	8	10	2.16	(1.10 ;3.22)		82
	4	10	2.68	(1.81 ;3.55)	101	
	2	7	3.06	(2.13 ;3.98)	115	
LA-2	12	9	2.10	(1.37 ;2.83)	79	
	6	7	2.13	(1.20 ;3.05)		80
	3	6	3.17	(2.35 ;3.99)		119
LA-12	12	8	2.23	(1.43 ;3.02)		84
	6	9	2.66	(2.00 ;3.31)		100
	3	9	2.76	(1.86 ;3.65)	104	

n = amount of animals in a group ; dissection 10 th day

Tab 7-2.

Antitumor effect of compounds LA-2 and LA-12 in comparison with PLATIDIAM inj. at animals with ascitic form of Ehrlich tumor (ATE) ; continual therapeutical regimen.

Mice ICR, females, 23.7 - 25.4 g. Inoculation of the tumor by i.p., inoculum of 0.2 ml of ascite. Beginning with the therapy 1st day after inoculation (9 x p.o., 1st-9th day, Platidiam 1x s.c. 1st day).

The table lists, with respect to the respective dosages, mean values of survival time, confidentiality intervals of the geometric mean for $P = 1 - \alpha = 0.95$ and relative values of mean survival times as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Geom. mean (days)	Confident. interval (days)	Survival (in % of control)	Note
control	0	10	11.4	(7.4 ;17.6)	100	
Platidiam	8	10	21.0	(16.2 ;27.1)	184	1)
	4	10	21.8	(19.5 ;24.3)	190	2)
	2	10	13.8	(8.7 ;21.6)	120	
LA-2	12	10	12.6	(8.4 ;18.9)	110	
	6	10	17.9	(12.1 ;26.4)	156	
	3	10	18.4	(11.5 ;29.6)	161	
LA-12	12	10	15.5	(9.3 ;25.8)	135	
	6	10	25.1	(22.7 ;27.7)	219	2)
	3	10	18.0	(12.6 ;25.7)	157	

n = amount of animals in a group

Statistically significant difference of the mean value against the control at significance level $\alpha = 1) 0.05, 2) 0.01$

Example 11

Illustration of antitumor activity of af-bis(acetato)-b-(1-adamantylamine)-c-ammin-de-dichloroplatinum(IV) complex (compound (I), A=1-adamantylamine, „LA-12“), inclusion drug form of LA-12 and af-bis(acetato)b-(1-amino-3,5-dimethyladamantan)-c-ammin-de-dichloroplatinum (IV) complex (compound (I), A= 1-amino-3,5-dimethyladamantane, „LA-15“) in mice with ATE after continual and intermitent oral administration and comparison with af-bis(acetato)-b-ammin-cd-dichloro-e-(cyclohexylamine)platinum (IV) complex (compound (I), A= cyclohexylamine, code JM216, „LA-2“ - Kelland et al., 1993) and with cis-diammin-dichloroplatinum(II) complex (NSC 119875, active substance of the preparation PLATIDIAM 10 inj.sicc.)

In an experiment with animals with ATE which was arranged analogically as in Example 10, the compound LA-12, its inclusion drug form and compound LA-15 were administered repeatedly in nine daily doses, namely at the 1st-9th day after innoculation, together with LA-2 p.o. in the same regimen. Platidiam was administered subcutaneously .

After termination of application, one half of animals in each dosage group was destroyed at 10th day after inoculation in ether narcosis, the ascits were sucked out after laparotomy and the mass of a tumor at each of the animals was determined from the difference of mass before and after sucking out the ascit. Ascitocrit in ascitic liquor of single animals was determined on microhematocrit centrifuge in heparinized capillary tubes of 75 mm length. The value of „total ascitocrit“ corresponding to a mass of cells in ascitic liquor has been determined from percentage of ascitocrit and mass of the tumor. Remaining animals were left for monitoring the survival time. In these animals, the survival time was monitored on daily basis. The dependence of the survival time value on the applied dose was evaluated in comparison with the reference group.

The single estimated time points as biological responses were evaluated by a test of equivalence of two mean values (Student's t-test). Geometric mean was calculated from single values of survival time, arithmetic means were calculated from single values of tumor mass and total ascitocrit. Difference between mean values was evaluated by a test of equivalence of two mean values (Student's t-test) under presumption of normal probability distribution of mass values as well as of total ascitocrit values and of logarithmic/normal distribution of temporal values, all under presumption of possible unknown disseminations. Those diferences in mean values, whose values of a test

criterion exceeded the critical value at the 5% and 1% significance level were evaluated as statistically significant and highly statistically significant, respectively.

The optimum dosage has been calculated from values of survival time according to the proportional risk model of Cox (Carter et al., 1982). Parameters of Weibull distribution and logarithmic transformation of introductory data were used for estimation of a basic and modified survival function from experimental data.

The inclusion drug form of LA-12 has increased the survival time in comparison with control group in statistically significant way and has been evaluated as antitumor effective similarly as Platidium in dosages 8 and 4 mg/kg s.c. x 1. The compounds LA-2, LA-12 and LA-15 didnot increase the survival time statistically significant in comparison with the control group (Tab. 8.1).

It has been observed that the treated animals exhibited lower average value of tumor mass in comparison with the untreated control group (Tab. 8-2) but that difference is not statistically significant.

Mean value of the mass of cell fraction of the tumor (total ascitocrit) has been statistically significant lower only in case of the compound LA-15 in a dose of 6mg/kg/day p.o. x 9 (Tab. 8-3) which represents an evidence of antitumor effect of said compound.

The results obtained are summarized in the following tables :

Tab 8-1.

Antitumor effect of compounds LA-2, LA-12, inclusion drug form of LA-12 and LA-15 in comparison with PLATIDIAM inj. at animals with ascitic form of Ehrlich tumor (ATE). Continual therapeutic regimen.

Mice ICR, females, 30.1-33.7 g. Inoculation of the tumor by i.p., inoculum of $5 \cdot 10^6$ tumor cells in 0.2 ml of the ascit. Beginning with the therapy 1st day after inoculation (9 x p.o. 1th-9th day , Platidium 1x s.c. 1st day).

The table lists, with respect to the respective dosages, the mean values of survival time, confidentiality intervals of the geometric mean for $P = 1 - \alpha = 0.95$ and relative values of mean survival time as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Geom. mean (days)	Confident. interval (days)	Survival (in % of control)	Note
control	0	10	8.9	(6.6 ;12.0)	100	
Platidiam	8	10	18.5	(13.6 ;25.1)	208	3)
	4	10	17.5	(15.0 ;20.5)	197	3)
	2	10	11.4	(7.9 ;16.3)	128	
LA-2	12	10	9.9	(6.4 ;15.4)	111	
	6	10	13.2	(8.7 ;20.0)	148	
	3	10	10.1	(6.2 ;16.3)	114	
LA-12	12	10	11.9	(7.1 ;20.1)	134	
	6	10	13.6	(8.6 ;21.4)	153	
	3	10	12.7	(8.4 ;19.4)	143	
LA-12,drug form	12	10	14.4	(10.3 ;20.0)	162	1)
	6	10	16.3	(12.3 ;21.5)	183	1)
	3	10	12.2	(8.1 ;18.5)	131	
LA-15	12	10	8.6	(5.7 ;12.9)	97	
	6	10	9.6	(6.1 ;15.0)	108	3)
	3	10	8.8	(5.8 ;13.4)	99	

n = amount of animals in a group

Statistically significant difference of the mean value against the control at significance level $\alpha =$ 1) 0.05, 2) 0.01, 3) 0.001

Antitumor effect of compounds LA-2, LA-12, inclusion drug form of LA-12 and LA-15 in comparison with PLATIDIAM inj. at animals with ascitic form of Ehrlich tumor (ATE). Continual therapeutic regimen.

Mice ICR, females, 30.1-33.7 g. Inoculation of the tumor by i.p., inoculum of $5 \cdot 10^6$ tumor cells in 0.2 ml of the ascit. Beginning with the therapy 1st day after inoculation (9 x p.o. 1th-9th day, Platidiam 1x s.c. 1st day).

The table lists, with respect to the respective dosages, the mean values of tumor mass, confidentiality intervals of the arithmetic mean for $P = 1 - \alpha = 0.95$ and relative values of mean tumor mass as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Arithm. mean (g)	Confident. interval (g)	Tumor mass (%)	Note
control	0	6	3.93	(1.54 ;6.32)	100	
Platidiam	8	8	2.36	(1.08 ;3.64)		60
	4	6	3.53	(1.93 ;3.13)		90
	2	7	2.83	(1.14 ;4.52)		72
LA-2	12	8	2.74	(1.73 ;3.75)	70	
	6	5	2.32	(0.84 ;3.80)		59
	3	7	3.53	(2.15 ;4.91)		90
LA-12	12	5	1.86	(0.27 ;3.45)		47
	6	6	3.07	(1.92 ;4.21)		78
	3	5	4.32	(3.24 ;5.40)		110
LA-12,drug form	12	7	4.03	(1.30 ;6.76)		102
	6	7	4.13	(2.21 ;6.05)		105
	3	7	3.93	(2.24 ;5.62)		100
LA-15	12	3	3.77	(1.53 ;6.01)		96
	6	6	2.08	(1.00 ;3.16)		53
	3	7	3.51	(2.12 ;4.91)	89	

n = amount of animals in a group, dissection 10th day

Tab 8-3.

Antitumor effect of compounds LA-2, LA-12, inclusion drug form of LA-12 and LA-15 in comparison with PLATIDIAM inj. at animals with ascitic form of Ehrlich tumor (ATE). Continual therapeutic regimen.

Mice ICR, females, 30.1-33.7 g. Inoculation of the tumor by i.p., inoculum of $5 \cdot 10^6$ tumor cells in 0.2 ml of the ascit. Beginning with the therapy 1st day after inoculation (9 x p.o. 1th-9th day, Platidium 1x s.c. 1st day).

The table lists, with respect to the respective dosages, the mean values of tumor mass, confidentiality intervals of the arithmetic mean for $P = 1 - \alpha = 0.95$ and relative values of mean tumor mass as a percentage of that of the control group.

Compound	Dosage (mg/kg/day)	n (j)	Arithm. mean (g)	Confident. interval (g)	Total ascitocrit ³⁾ (%)	Note
control	0	6	0.68	(0.59 ; 0.78)	100	
Platidium	8	5	0.68	(0.62 ; 0.75)		100
	4	6	0.80	(0.54 ; 1.00)		116
	2	7	0.79	(0.39 ; 1.18)		115
LA-2	12	8	0.65	(0.49 ; 0.82)	95	
	6	5	0.69	(0.34 ; 1.03)		100
	3	6	0.74	(0.64 ; 0.83)		108
LA-12	12	5	0.44	(0.19 ; 0.69)		64
	6	6	0.68	(0.46 ; 0.89)		99
	3	5	0.68	(0.31 ; 1.06)		100
LA-12, drug form	12	7	0.80	(0.46 ; 1.15)		117
	6	7	0.60	(0.40 ; 0.81)		88
	3	7	0.93	(0.24 ; 0.62)		99
LA-15	12	3	0.82	(0.14 ; 1.78)		120

- 30 -

	6	6	0.40	(0.19 ;0.61)	59	
2)						
	3	7	0.84	(0.71 ;0.97)	123	1)

n = amount of animals in a group, dissection 10th day


Statistically significant difference of the mean value against the control at significance level $\alpha =$ 1) 0.05, 2) 0.01

3) Total ascitocrit - mass of cell fraction of a tumor

M 04-31-05-00

CLAIMS

1. A platinum complex with oxidation number IV of formula (I)




wherein

X represents a halogen atom,

B represent, independently to each other, a halogen atom, a hydroxyl group or a carboxylate group containing 1 to 6 carbon atoms, and

A represents a group $-\text{NH}_2\text{-R}$, wherein R is a tricyclic hydrocarbon moiety containing 10 to 14 carbon atoms, which may be optionally substituted on the tricyclic ring by one or two alkyl group(s) each containing 1 to 4 carbon atoms.

2. An inclusion complex of a platinum complex with oxidation number IV of formula (I)



wherein

X represents a halogen atom,

B represent, independently to each other, a halogen atom, a hydroxyl group or a carboxylate group containing 1 to 6 carbon atoms, and

A represents a group $-\text{NH}_2\text{-R}$, wherein R is a tricyclic hydrocarbon moiety containing 10 to 14 carbon atoms, which may be optionally substituted on the tricyclic ring by one or two group(s) each containing 1 to 4 carbon atoms,


with beta- or gamma-cyclodextrin which may be optionally substituted by hydroxyalkyl groups containing 1 to 6 carbon atoms.



AMENDED SHEET
 AMENDED SHEET (ARTICLE 19)

32
04-05-00

3. A complex according to claim 1 of formula (I) wherein A represents an adamantylamino group and X and B have the meaning as defined in claim 1.
4. A complex according to claim 1 of formula (I) wherein A represents a 3,5-dimethyladamantylamino group and X and B have the meaning as defined in claim 1
5. A process for the preparation of the platinum complex of formula (I) according to claim 1 characterized in that a complex of divalent platinum of formula (II)



wherein X and A have the meaning as defined in claim 1 ,

is oxidized at platinum atom by hydrogen peroxide with formation of a platinum(IV)dihydroxo-complex and, optionally,

the hydroxy groups of the said complex are substituted with carboxylate groups by action of an acylating agent.

6. A process for the preparation of an inclusion complex of the platinum complex of formula (I) with beta- or gammacyclodextrin which may be optionally substituted by hydroxyalkyl groups containing 1 to 6 carbon atoms according to claim 2, said process being characterized in mixing a solution of the platinum complex of formula (I) in an organic solvent with an aqueous solution of beta- or gamma cyclodextrin which is optionally substituted by hydroxyalkyl groups containing 1 to 6 carbon atoms, following by evaporation of the solvents from the obtained solution.

7. The platinum complex of formula (I) or its inclusion complex with beta-or gammacyclodextrin according to claim 1 or 2 for use as a pharmaceutical.

8. A pharmaceutical composition for therapy of oncological diseases characterised in that it contains at least one platinum complex of formula (I) or its inclusion complex with beta-or gamma cyclodextrin according to claim 1 or 2 as the active substance, and at least one pharmaceutical excipient.



SUBSTITUTE SHEET

AMENDED SHEET (ARTICLE 19)